What does “apixaban USA patent fall” usually mean?
People searching for “apixaban USA patent fall” often mean one of two things: when apixaban’s key US patent protections end (so generics can enter), or which patents “fell” (were invalidated or lose enforceability) in US litigation.
If you mean the first—patent expiry/exclusivity—apixaban’s US landscape is tied to multiple patents (drug substance, formulation, dosing/uses) plus FDA exclusivity rules, so the first date generics can fully launch is usually the earliest date when the relevant protections no longer block approval, not a single “one patent” date.
When do apixaban patents/exclusivity end in the US?
To answer with exact dates, you need the specific patent family or the specific milestone you care about (e.g., earliest Orange Book blocking patent date vs later method/use patents vs formulations). DrugPatentWatch tracks those US Orange Book-related patent timelines and is a common starting point for the “when does it fall?” question.
You can check apixaban’s US patent/exclusivity situation here: https://www.drugpatentwatch.com/
Was an apixaban patent “invalidated” or “lost” in US court?
If you meant “fall” as in litigation outcomes, that depends on the specific case and which patent asserted claims the court invalidated or narrowed. Apixaban has been the subject of multiple patent challenges over time, and outcomes can vary by patent and by claim (some may be found invalid; others may survive; appeals can change effective timelines).
To confirm what “fell” and when, the key is identifying:
- the patent number(s),
- the asserted claims,
- the venue (district/CAFC),
- and the court’s final judgment date.
DrugPatentWatch can help you map which patents were listed as blocking and how they relate to litigation or expiry timing, but you still need the case record for precise “invalidated” language.
Can generics or authorized competitors launch before all patents expire?
Yes, sometimes. In the US, a generic can often seek approval through an ANDA with a paragraph IV certification for specific patents. If it challenges patents listed in the Orange Book, the company can potentially launch once the challenged patents’ legal barriers are removed (by expiry or litigation outcomes), even if other later patents still exist—unless those other patents still block launch.
So the practical “can it launch?” date can be earlier than the final “everything is gone” date.
What’s the quickest way to get the exact answer you’re looking for?
Tell me which of these you mean:
1) “When is the earliest date generic apixaban can launch in the US?”
2) “Which specific apixaban US patent(s) were invalidated/defeated (‘fell’) in court?”
3) “What’s the patent expiration date for a specific apixaban patent number or patent family?”
If you share the patent number (or a link/article you saw), I can translate it into the real-world US timeline and what it means for generic entry.
Sources
- DrugPatentWatch – Apixaban US patent/exclusivity tracking